ALNY Alnylam Pharmaceuticals, Inc. gains 17% Jan 27, 2021

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. Its pipeline of investigational RNAi therapeutics is focused on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of transthyretin-mediated amyloidosis (ATTR); Fitusiran, an investigational RNAi therapeutic that is in Phase I/II clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran (ALN-PCSsc), which is in Phase II clinical trial for hypercholesterolemia. Its early stage clinical programs include Givosiran that is in Phase I trial to treat acute hepatic porphyrias; ALN-CC5 for the treatment of complement-mediated diseases; ALN-GO1 to treat primary hyperoxaluria 1; ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; and ALN-HBV for the treatment of Hepatitis B virus. The company has strategic alliances and collaboration agreements primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc.; and Arbutus Biopharma Corporation. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.http://www.priceseries.com/trade/ALNY-Alnylam-Pharmaceuticals-Inc-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2021010720210127.html

ALDX Aldeyra Therapeutics, Inc. gains 31% Jan 27, 2021

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for diseases caused by inflammation and inborn errors of metabolism in the United States and internationally. It is developing NS2, a small molecule designed to trap and allow for the degradation of aldehydes. Its product is used for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, sjogren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts.http://www.priceseries.com/trade/ALDX-Aldeyra-Therapeutics-Inc-stock-gains-31-percent-a-Trade-Record-by-priceSeries-2021010720210127.html

AIRG Airgain Inc gains 17% Jan 27, 2021

Airgain, Inc. designs, develops, and engineers antenna products for original equipment and design manufacturers, chipset vendors, service providers, and value added resellers and distributors worldwide. The company's products include MaxBeam embedded antennas; profile embedded antennas; profile contour embedded antennas; ultra-embedded antennas; OmniMax high performance external antennas; MaxBeam carrier class antennas; and SmartMax embedded antennas, as well as automotive, fleet, public safety, and M2M antennas. It provides embedded antenna technologies to enable high performance wireless networking across a range of devices and markets, including consumer, enterprise, and automotive. The company was formerly known as AM Group and changed its name to Airgain, Inc. in 2004. Airgain, Inc. was founded in 1995 and is headquartered in San Diego, California.http://www.priceseries.com/trade/AIRG-Airgain-Inc-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2021011120210127.html

ACER ACER Therapeutics Inc. gains 43% Jan 27, 2021

Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases based on its proprietary T-cell technology. The company's lead product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. It is also developing OPX-212 as an autologous T-cell immunotherapy that is in preclinical development to treat neuromyelitis optica. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics, Inc. was founded in 2003 and is based in The Woodlands, Texas.http://www.priceseries.com/trade/ACER-ACER-Therapeutics-Inc-stock-gains-43-percent-a-Trade-Record-by-priceSeries-2021011220210127.html

WK Workiva Inc. gains 72% Jan 25, 2021

Workiva Inc., together with its subsidiaries, provides connected reporting and compliance platform worldwide. The company offers Workiva platform that offers controlled collaboration, data linking, data integrations, granular permissions, process management, and full audit trail services; and Wdata, which includes data integration and preparation tools that enables customers to connect data from enterprise resource planning, governance risk and compliance, and customer relationship management platforms, as well as from other third-party cloud and on-premise systems. It serves public and private companies, government agencies, and higher-education institutions. Workiva Inc. was founded in 2008 and is headquartered in Ames, Iowa.http://www.priceseries.com/trade/WK-Workiva-Inc-stock-gains-72-percent-a-Trade-Record-by-priceSeries-2020110220210125.html

VNCE Vince Holding Corp. gains 19% Jan 22, 2021

Vince Holding Corp. engages in the design, merchandise, and sale of various contemporary fashion brand products in the United States and internationally. It operates through two segments, Wholesale and Direct-To-Consumer. The company offers a range of women's products, such as cashmere sweaters, silk blouses, leather and suede leggings and jackets, dresses, denims, tanks, T-shirts, pants, handbags, and outerwear under Vince brand; and men's products comprising T-shirts, knit and woven tops, sweaters, denim, pants, blazers, outerwear, and leather jackets under Vince brand. It also provides women's and men's footwear, and children's apparel products. The company sells its products directly to consumers through its branded specialty retail stores and outlet stores, as well as through Vince.com, an e-commerce platform; and to department stores and specialty stores. As of January 30, 2016, it operated 48 retail stores, including 34 company-operated full price stores and 14 company-operated outlet stores, as well as VINCE.com and e-commerce sites; and sold its products to consumers at approximately 2,500 distribution locations in 38 countries. The company was formerly known as Apparel Holding Corp. and changed its name to Vince Holding Corp. in November 2013. Vince Holding Corp. was founded in 2002 and is based in New York, New York.http://www.priceseries.com/trade/VNCE-Vince-Holding-Corp-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2021010620210122.html

SMLP Summit Midstream Partners, LP gains 15% Jan 25, 2021

Summit Midstream Partners, LP focuses on owning, developing, and operating midstream energy infrastructure assets primarily shale formations in North America. The company provides natural gas gathering, treating, and processing services. It operates in five unconventional resource basins, including the Appalachian Basin, which comprises the Utica and Point Pleasant shale formations in southeastern Ohio, and the Marcellus Shale formation in northern West Virginia; the Williston Basin that consists the Bakken and Three Forks shale formations in northwestern North Dakota; the Fort Worth Basin, which includes the Barnett Shale formation in north-central Texas; the Piceance Basin that comprises the Mesaverde formation, and the Mancos and Niobrara shale formations in western Colorado and eastern Utah; and the DJ Basin, which includes the Niobrara shale formation in northeastern Colorado. The company serves crude oil and natural gas producers. Summit Midstream GP, LLC operates as a general partner of the company. Summit Midstream Partners, LP was founded in 2009 and is headquartered in The Woodlands, Texas.http://www.priceseries.com/trade/SMLP-Summit-Midstream-Partners-LP-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2021011220210125.html

SCON Superconductor Technologies Inc. gains 21% Jan 22, 2021

Superconductor Technologies Inc. develops and commercializes high temperature superconductor (HTS) materials and related technologies in the United States. It focuses on using Conductus wire products for superconducting high power transmission cable, superconducting fault current limiters, and high field magnet applications. Superconductor Technologies Inc. was founded in 1987 and is headquartered in Austin, Texas.http://www.priceseries.com/trade/SCON-Superconductor-Technologies-Inc-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2021011320210122.html

QUMU Qumu Corp. gains 64% Jan 25, 2021

Qumu Corporation engages in enterprise video content management software business. The company's tools enable businesses to create, manage, secure, distribute, and measure the success of their videos. It offers enterprise video content management software products through the sale of software licenses and hardware, software on a server appliance, software-enabled devices, and a cloud-hosted software-as-a-service platform. The company also provides maintenance and support, professional, and other services. It markets its products to customers in North America, Europe, and Asia. The company was formerly known as Rimage Corporation and changed its name to Qumu Corporation in September 2013. Qumu Corporation was founded in 1978 and is headquartered in Minneapolis, Minnesota.http://www.priceseries.com/trade/QUMU-Qumu-Corp-stock-gains-64-percent-a-Trade-Record-by-priceSeries-2020120420210125.html

PACB Pacific Biosciences of California, Inc. gains 36% Jan 25, 2021

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and exonucleases. In addition, it provides binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprises reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences has collaboration with Asuragen to develop assays for carrier screening and other applications based on SMRT sequencing technology and AmplideX PCR chemistry; Invitae Corporation focuses on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.http://www.priceseries.com/trade/PACB-Pacific-Biosciences-of-California-Inc-stock-gains-36-percent-a-Trade-Record-by-priceSeries-2021010420210125.html